文献速递白血病淋巴瘤

BRAFV600E加速B细胞白血病小鼠模型的疾病进展并增强免疫抑制

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia.
PubMed 文献 · Blood Adv · 2017-10-30

研究构建了B细胞限制性表达BRAFV600E的Eµ-TCL1慢性淋巴细胞白血病(CLL)小鼠模型,发现BRAFV600E突变使白血病发生显著提前(中位4.9 vs 8.1个月,P < .001)且生存期显著缩短(中位7.3 vs 12.1个月,P < .001),突变不影响B细胞增殖但减少自发凋亡,并增强T细胞耗竭表型及PD-L1表达,体外可被BRAFV600E抑制逆转。

要点

  • BRAFV600E使Eµ-TCL1小鼠白血病发生提前(中位4.9 vs 8.1个月,P < .001)且生存期缩短(中位7.3 vs 12.1个月,P < .001)。
  • BRAFV600E不影响B细胞增殖但减少自发凋亡,并增强T细胞耗竭表型及CD11b+细胞PD-L1表达。
  • BRAFV600E表达的CLL细胞系更强抑制抗CD3/CD28诱导的T细胞增殖,该效应可被BRAFV600E抑制逆转。

核心结论

  • BRAFV600E在B细胞白血病中具有免疫抑制作用,并引入了一个可用于开发同时靶向肿瘤细胞和肿瘤介导免疫逃逸的合理联合策略的新模型。

研究设计与样本

  • 研究构建了B细胞限制性表达BRAFV600E的Eµ-TCL1慢性淋巴细胞白血病(CLL)小鼠体内播散性白血病模型,并与BRAF野生型对照比较。
  • 结果在同源移植BRAFV600E白血病细胞的小鼠中得到验证,并使用表达BRAFV600E的CLL细胞系进行体外T细胞增殖抑制实验。

主要发现

  • BRAFV600E组白血病发生显著早于BRAF野生型组(中位4.9 vs 8.1个月;P < .001)。
  • BRAFV600E组寿命显著短于BRAF野生型组(中位7.3 vs 12.1个月;P < .001)。
  • BRAFV600E表达不影响B细胞增殖但减少自发凋亡。
  • BRAFV600E突变白血病产生更强的T细胞效应,表现为耗竭免疫表型和CD44+ T细胞百分比,以及CD11b+细胞上PD-L1表达增加。
  • 表达BRAFV600E的CLL细胞系更强抑制抗CD3/CD28诱导的T细胞增殖,该抑制可被BRAFV600E抑制逆转。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutated mitogen-activated protein kinase (MAPK) pathway components promote tumor survival, proliferation, and immune evasion in solid tumors. MAPK mutations occur in hematologic cancers as well, but their role is less clear and few models are available to study this. We developed an in vivo model of disseminated BRAFV600E B-cell leukemia to determine the effects of this mutation on tumor development and immune evasion. Mice with B-cell-restricted BRAFV600E expression crossed with the Eµ-TCL1 model of chronic lymphocytic leukemia (CLL) developed leukemia significantly earlier (median, 4.9 vs 8.1 months; P < .001) and had significantly shorter lifespan (median, 7.3 vs 12.1 months; P < .001) versus BRAF wild-type counterparts. BRAFV600E expression did not affect B-cell proliferation but reduced spontaneous apoptosis. BRAFV600E-mutant leukemia produced greater T-cell effects, evidenced by exhaustion immunophenotype and CD44+ T-cell percentage, as well as increased expression of PD-L1 on CD11b+ cells. Results were confirmed in syngeneic mice engrafted with BRAFV600E leukemia cells. Furthermore, a BRAFV600E-expressing CLL cell line more strongly inhibited anti-CD3/CD28-induced T-cell proliferation, which was reversed by BRAFV600E inhibition. These results demonstrate the immune-suppressive impact of BRAFV600E in B-cell leukemias and introduce a new model to develop rational combination strategies targeting both tumor cells and tumor-mediated immune evasion.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tsai YT, Lakshmanan A, Lehman A, et al. BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Adv. 2017. PMID: 29296862. doi:10.1182/bloodadvances.2017006593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。